News

Bayer Satellite Symposium at 2016 SSc World Congress: SGC Stimulation and Exclusive Interview with Lead Investigator

https://sclerodermanews.com/wp-content/uploads/videos/Sequence%2001_1.mp4             Scleroderma News Today’s exclusive interview with Professor Christopher Denton, lead investigator of two Phase 3 clinical trials assessing Bayer’s class of sGC stimulators, Adempas, in PAH and PAH-CTD patients.   The 4th Systemic Sclerosis World Congress opened on Friday…

SSc-associated PAH Patients with Anti-U1 RNP Antibodies May Have More Favorable Outcomes

Patients with connective tissue disease or systemic sclerosis associated with pulmonary arterial hypertension (PAH) who are positive for anti-U1 RNP antibodies have more a favorable disease prognosis than patients without these antibodies, a study published in the journal Arthritis & Rheumatology showed. Anti-U1 RNP antibodies are autoantibodies directed at nuclear proteins. They are…

Potential Scleroderma Gene Therapy Moving into Preclinical Dosing Study, Fibrocell Reports

Fibrocell Science, Inc., recently highlighted the latest advancements in its pipeline of products focused on autologous cell and gene therapy treatments for several conditions, including scleroderma. The company’s autologous fibroblast technology uses a patented manufacturing process that involves collecting small skin biopsies from patients, separating the tissue into its component cells, and then…